Rare diseases reveal that our sense of identity rests on fragile biological infrastructure, much of it operating outside ...
Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...
Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback